|Bid||10.08 x 1200|
|Ask||10.09 x 1400|
|Day's Range||9.96 - 10.06|
|52 Week Range||3.75 - 16.86|
|Beta (3Y Monthly)||4.10|
|PE Ratio (TTM)||33.51|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A new study says marijuana is the fastest growing labor market in the U.S. Yahoo Finance's Zack Guzman & Jeanie Ahn, along with 'Afford Anything' Podcast Host Paula Pant discuss with Acreage Holdings CEO Kevin Murphy.
Will the FDA continue its e-cig crackdown? Yahoo Finance's Zack Guzman and Sibile Marcellus, along with author and career coach Charreah Jackson discuss.
HENDERSON, NV / ACCESSWIRE / March 20, 2019 / Legal cannabis cultivation in the U.S. consumes an estimated 1.1 terawatt-hours of electricity a year, according to the 2018 Cannabis Energy Report, published ...
The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued. For example Aurora Cannabis (ACB) - which has doubled year-to-date, is now facing a downside risk of 8% according to the Street. So with that in mind we focused in on stocks that still have massive upside potential ahead. We used TipRanks to focus in on the latest ratings from analysts with the strongest stock picking track record. Without further ado, here are three of the best cannabis stocks to be looking at right now:Aphria Has More Room to RunOver the last three years, Aphria (APHA) shares have exploded by over 850%, and according to the Street significant further upside potential lies ahead.That’s despite a horrendous 2018, which featured a hostile takeover attempt, the exit of its CEO and allegations from a short-seller that insiders profited from acquiring international businesses at highly inflated prices. This was the central accusation of a short report that roiled the stock price, and renewed concerns about the company’s corporate governance.Luckily the most serious allegations have now been refuted. A special board committee found that the price paid for businesses in Latin America was acceptable and that these assets are now progressing according to plan. And with newly-appointed chairman Irwin Simon now acting as CEO, short-seller Quintessential is appeased, tweeting: “With a new management team the company has a chance to a brighter future and we are accordingly moving on to new projects.” Simon is the founder, and former CEO of multi-billion company Hain Celestial Group.In short, this low-cost cannabis producer is ready to rebound. This is reflected by recent ratings from the Street. Most notably, top-rated Clarus analyst Noel Atkinson has just reiterated his buy rating on APHA with a price target of $19.25. This translates into sizeable upside potential of over 85% from the stock’s current share price of $9.63. (To watch Atkinson's track record, click here)According to Atkinson the company needs to stop looking back and start executing to move the ball forward. He believes Aphria’s list of near-term operational milestones is significant, and successful execution could transform the company both in terms of financial results and investor sentiment. “If management can execute, there is the potential for a very substantial re-rating of the stock price from current levels” the analyst tells investors.Overall, Wall Street’s confidence backing this cannabis stock is strong, with TipRanks analytics showcasing APHA as a Strong Buy. Based on 6 analysts polled in the last 3 months, 5 are bullish on Aphria stock, while only 1 remains sidelined. The 12-month average price target stands at $15.33, marking over 50% upside from where the stock is currently trading. (See APHA's price targets and analyst ratings on TipRanks)Zynerba Stock Looks Less FragileZynerba (ZYNE) focuses on transdermal cannabinoid therapeutics. Its goal is to improve the lives of patients affected by rare neuropsychiatric conditions including Fragile X syndrome and autism spectrum disorder. Currently the company is trialing a groundbreaking cannabinoid (CBD) gel. This is the first and only patented permeation-enhanced CBD gel for delivery through the skin and into the circulatory system.According to ZYNE, the gel offers multiple advantages when compared to the more traditional oral delivery. By skipping the digestive process, ZYNE can minimize psychoactive effects, limit drug-drug interaction, and avoid digestion of the drug by the liver.And for investors, now’s the time to start taking a closer look at Zynerba’s investing potential. That’s because this cannabis biotech is gearing up for a transformational 2019 according to five-star HC Wainwright analyst Oren Livnat. Today, Livnat reiterated his buy rating on ZYNE with a $23 price target, which indicates jaw-dropping upside of over 350%. (To watch Livnat's track record, click here)The key data to look out for comes from Zynerba’s lead Fragile X (FXS) program. ZYNE continues to enroll patients for the pivotal Phase 3 study (CONNECT-FX), and the all-important data is expected in 2H19. Livnat is optimistic for positive data, although he admits that this is a risky call given other companies’ failure in this indication.Livnat noted, "We reiterate our Buy, rating and see the current $105M market cap ($27M EV) leaving remarkable upside potential on positive data; as our $23 price target still reflects only a 35% probability of success in FXS.”Overall, this cannabis-related player stands as a 'Strong Buy' name among Wall Street analysts. In the last 12 months, ZYNE stock has won four 'buy' ratings vs. only one 'hold' rating. With a return potential of over 300%, the stock's consensus price target lands at $20. (See ZYNE's price targets and analyst ratings on TipRanks)Arena Stock Falls Under the RadarHere we have a promising biotech that is currently under-the-radar for most investors. Unlike Zynerba, Arena (ARNA) devotes some of its pipeline to CBD therapeutics, while also devoting some of its pipeline to non-cannabinoid medicine.This means that even though its most advanced drug currently in trial is Etrasimod (for colitis, Crohn’s and atopic dermatitis), for cannabis investors Olorinab is the key focus. Also known as APD371, Olorinab is an oral agonist of cannabinoid receptor 2 (CB2), which is part of the natural cannabinoid receptor system found in our bodies. The drug is designed to treat pain associated with gastrointestinal diseases like IBS and Crohn’s- a large and growing market.And the best part is that these drugs could ultimately reduce the need for highly addictive opioid medications. As Bruce Yacyshyn, medical director at UC Health University Hospital, says: “There is a strong clinical need for non-opiate treatments for the management of chronic abdominal pain in patients with gastrointestinal disorders, including Crohn’s disease, ulcerative colitis and irritable bowel syndrome.”As for the timeline, Olorinab Phase 2 trial in IBS pain is expected to begin in 2H19. Cantor Fitzgerald’s Alethia Young is keeping a close eye on these developments, writing “Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim.”She reiterates her buy rating on Arena with a $62 price target- indicating 33% upside potential from current levels. Alongside Young, Needham’s Alan Carr is the only other top analyst who has published a recent rating on Arena. He also rates the stock a Buy, writing “we think olorinab remains an unappreciated potential opportunity with commercial synergies with etrasimod.”To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Last Minute Thought: Buy or Sell Micron (MU) Stock Before 2Q19 Report? * Apple (AAPL): iMac Update Should Not Affect the Stock Negatively -- Here's Why * There’s a Lot to Like About AMD Stock, But Don't Buy Into the Google Hype * A Big Week for Cannabis Stocks as Tilray (TLRY) Posted 110% Revenue Growth
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The marijuana stock market has garnered significant media attention over the last few months as the ancillary industry has quickly shifted from being a lesser-known collective of companies to a valuable asset that investors are hot to have in their portfolios. Perhaps the most important reason that investors are interested in ancillary cannabis companies, rather than pure-play cannabis stocks, is that these tertiary companies are not nearly as volatile. This sect of the cannabis sector covers a myriad of companies relating to everything from packaging to digital and more.
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.Aphria Inc. APHA-CA : "The guy who actually I think runs it day to day is Irwin Simon, our old friend from Hain Celestial, and I think that Irwin can pull something off here.
As a result, investment houses are taking a fresh look at the sector -- and the latest development is an initiation of coverage by Seaport Global Securities. The company officially reviewed and rated several companies in the cannabis industry. Seaport analyst Brett Hundley and Luke Perda said that they expect to see the industry rise from $12 billion in value today to almost $630 billion in due time.
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / It's quite astounding that the marijuana stock market continues to receive so much attention despite the nascent nature of the cannabis industry. Having said that, the cannabis industry has seen a boom in excitement this past year as a result of lawmakers pushing for legislation in support of marijuana legalization. Global Consortium Inc (OTC:GCGX), Aphria Inc (APHA), Emerald Health Therapeutics Inc (EMHTF), and Innovative Industrial Properties Inc (IIPR) are 4 marijuana stocks heating up on Monday.
Harvest Health and Recreation Inc. said Monday that it plans to buy rival cannabis company Verano Holdings LLC for $850 million in stock. Harvest Health trades on the Canadian Securities Exchange and over the counter in the U.S. and went public in November on the CSE. Harvest Health's over the counter stock surged more than 12% in Monday trading. In a press release, Harvest Health said the acquisition cost was based on its share price of $C8.79 ($6.55) and that upon completion the deal it would operate 30 retail stores, eight grow sites and seven manufacturing facilities. Harvest Health has aggressive growth plans and said in the release by the end of 2019, it will have 70 shops, 13 pot farms and 13 manufacturing facilities. Sol Global Investments Corp. has a 15% stake in Verano, which Sol says is worth $127.5 million. Sol Global's chief investment officer and chairman of the board is Andy DeFrancesco, who short sellers Hindenburg Research and Quintessential Capital Management allege was involved with a pump and dump scheme related to Canada-based Aphria Inc.
If you own Aurora Cannabis (NYSE:ACB) stock, Cowen & Co. analyst Vivien Azer's February 5 comments about the Canadian company, were music to your ears. Also, getting some love from the analyst was Cronos Group (NASDAQ:CRON) and CRON stock, which she believes is doing an excellent job in the global medical cannabis market. Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhile Azer sees Aurora becoming profitable ahead of other large cannabis producers, including Canopy Growth (NYSE:CGC) and Aphria (NYSE:APHA), it's her comments about Cronos' asset-light model that's got me interested. She's got a good track record on cannabis stocks, ranked 64 out of 5,220 analysts on TipRanks.Back in December, Azer raved about Cronos' substantial investment from Altria (NYSE:MO). "While the potential uses of cannabinoids are vast, Cronos believes the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent and scalable production of a full spectrum of the roughly 100 cannabinoids, not just THC and CBD," Azer wrote in a note to clients. "Together, Cronos can leverage Altria's operational capabilities and expertise in order to create value-added form factors while focusing on ingredient composition without reliance on massive cultivation (farming) infrastructure."Translation: Cronos sees much greater value focusing on the finished goods and not so much on the cultivation of dried leaf. Shift in FocusIf I didn't know any better, I'd say that's a page right out of Altria's playbook. The cigarette maker owns none of the tobacco it sources. Its strength is manufacturing the cigarettes in mass quantities and efficiently getting them to customers. * 7 Chinese Stocks to Buy for the 2019 Rebound It's a big reason why I believe Altria's 45% stake in Cronos was a steal at $1.8 billion. "While Cronos doesn't have anywhere near $1.5 billion in revenue [Altria paid more than $14 billion for 35% of Juul] -- the cannabis company had just CAD$3.8 million in its most recent quarter -- it gives Altria a platform for growth in a market that's destined to be much bigger on a global basis than e-cigs could ever hope to be," I wrote on Dec. 31.Source: New Frontier DataLong before the recreational use of marijuana was legalized in Canada, I argued that tobacco companies would be the ideal group to solve supply issues that were cropping up in 2014, and still exist today. So, the fact that Altria's now involved is great news for the cannabis industry as a whole. And great news for CRON stock holders. A Safer AlternativeAlthough Cowen's Azer likes Cronos Group stock, she feels the valuation is much too frothy. Currently trading above CAD$30, Azer has a 12-month target price of CAD$29, which means one of three things is going to happen.The first scenario is CRON stock goes sideways for the next 12 months -- it's up 119% year to date through March 6. The second scenario is that it falls in value at which point she'd be a buyer. In the third, she's wrong about the valuation and it continues to move higher. I don't know about you, but a coin toss is the only way I'm going to be able to decide the potential outcome. Which means there ought to be a safer alternative. And there is.Last July, I recommended that anyone interested in Canopy Growth stock should hedge their bets by putting 50% of any dollar amount contemplated in Constellation Brands (NYSE:STZ), 25% in Canopy Growth, and the remaining 25% into the Horizons Marijuana Life Sciences Index ETF (OTCMKTS:HMLSF), which has Cronos, Canopy, and Aurora as the top three holdings. If you followed this route, a $10,000 investment is worth $10,590 through March 7. While that 5.9% gain is not exactly a home run, I don't think anyone expected Constellation Brands to lose so much value -- more than 23% -- when Canopy Growth itself is up 50% over the past eight months. The Nasdaq Composite index is down 4.3% in the same period. * 9 Trade War Stocks to Sell on U.S.-China Deal News The valuation mismatch should disappear over the next 12 months. When it does, investors will be way ahead. How to Play CRON StockMy three favorite cannabis stocks are Cronos, Canopy Growth, and Hexo (AMEX:HEXO).Following my suggestion for Canopy Growth, I would do the same for Cronos and Hexo, which means adding three new holdings, including Altria. Only the weightings would be a little different.In this case, I would weight each of the individual cannabis companies at 15%, Constellation Brands and Altria at 20% each, and the remaining 15% in the Horizons ETF.When the you-know-what hits the fan, your downside will be better protected. As of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Should Be Worried About a Data Dividend * 5 Cheap ETFs Worth Considering * 7 Cheap Stocks Under $5 That Could Soar Compare Brokers The post Hereas a Safer Cannabis Investment Move If You Like CRON Stock appeared first on InvestorPlace.
Typically, small-to-mid cap stock companies fare much better in volatile market conditions because, whereas larger companies are burdened by bureaucratic practices. CLS Holdings USA Inc (OTC:CLSH), Cronos Group Inc (NASDAQ:CRON), Aphria Inc (APHA), and Tilray Inc (NASDAQ:TLRY) are 4 marijuana companies testing their limits on Thursday. CLS Holdings USA Inc (OTC:CLSH) is a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiaries.
Earlier this week, Aurora Cannabis (NYSE:ACB) enjoyed a surge in momentum, leaping over 9% on Tuesday's session. But without any fresh fundamental drivers, it was easy to pinpoint why Aurora Cannabis stock took off.Source: Shutterstock Cowen & Co analyst Vivien Azer initiated coverage of the company with an "outperform" rating. Moreover, she set a $14 price target for ACB stock, representing a 77% premium against current levels. Since shares are already up over 61%, such resounding bullishness raised eyebrows.However, Azer wasn't just spitting out numbers for the fun of it. Backing her thesis is Aurora's "large cultivation footprint." Key acquisitions, such as January's Whistler Medical Marijuana buyout, will enable ACB to grow its domestic and international presence. Already, the company has 20% market share in its native Canada.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith continued advancements, Azer believes that ACB will deliver positive earnings by its fiscal fourth quarter in June. If so, Aurora Cannabis stock easily outshines rivals like Canopy Growth (NYSE:CGC) and Aphria (NYSE:APHA).Given a prominent voice in the legal-marijuana space advocating for Aurora, it seems a no-brainer. However, ACB stock, like any other name in the industry, has suffered wild swings in market value. As a result, conservative investors have avoided marijuana stocks, especially with the major indices performing poorly in recent sessions. * 7 Dow Jones Stocks to Buy In addition, rapid-fire growth has a dilutive effect. For instance, Aurora's $175 million Whistler buyout was an all-equity one. When you look at the company's other acquisitions, you'll notice a similar trend. While such decisions save vital cash funds, they also negatively impact Aurora Cannabis stock.If that wasn't enough of a concern, shares fell a sizable 2.6% on Wednesday. Is this a warning to avoid ACB stock? The Long Game Benefits Aurora Cannabis StockGiven this contrasting perspective, Aurora has the appearance of a classic bull-trap: shares attract investors on superficial information, but the fine print ultimately upends them.Indeed, when you drill into the granularity, Aurora Cannabis stock has "bad deal" written all over it. For example, Whistler has a production capacity of a little over 5,000 kilograms annually. That's nothing when you compare it to ICC Labs, another Aurora buyout. ICC churns out a whopping 450,000 kilograms annually.Aurora paid $290 million (in ACB stock) for ICC, while it paid $175 million for Whistler. Yes, the Whistler buyout is cheaper, but it's yielding 1% of ICC's production capacity. Has management started smoking their botanical inventory?Actually, the Whistler deal is one of the smartest moves the company has made. It just requires a longer-term approach to appreciate it.Here's the situation with the legal-marijuana industry: we're in the second leg of a multi-phase race. The first leg was the introductory period. This is where investments like Aurora Cannabis stock jumped higher simply because it exists in the cannabis space. Like I mentioned in prior stories, a previously illegal market found legality, naturally boosting investor sentiment.But now that everyone and their dog competes in the cannabis space, pure production stats no longer provides differentiation. Don't get me wrong: ACB stock clearly benefits from expansionary efforts. However, in the second leg, it's not just about quantity, but rather quality.What makes Whistler special? According to its PR profile, the company "commercialized more than 30 flower varieties and strain-specific oil products, from an extensive genetics bank of over 150 strains."This fact should actually be at the top of Aurora's marketing campaign. Patience Is Key for ACB StockLet's consider what happens several years down the line. Based on shifting political sentiment towards progressivism, the federal government will likely de-schedule marijuana. When that happens, anybody that shops at Home Depot (NYSE:HD) can theoretically grow their own weed.Under this environment, what incentivizes a pothead or a patient to fork over their money to a weed company? Surely, it's not quantity nor accessibility, since growing marijuana isn't brain surgery. What matters are strains and compounds that address specific symptoms, or induce a particular experience.Through the Whistler acquisition, Aurora wins on the quality department. With its other capacity-friendly buyouts, ACB ensures that it can supply that demand.Rather than being dilutive, the company's shopping spree is actually accretive. You just have to extend your timeframe.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Should Be Worried About a Data Dividend * 5 Cheap ETFs Worth Considering * 7 Cheap Stocks Under $5 That Could Soar Compare Brokers The post Stay the Course With Aurora Cannabis Stock appeared first on InvestorPlace.
Sans one-time benefits and fair-value adjustments, marijuana stock income statements have been downright ugly.
Why Aphria Could Squeeze Out Short Sellers(Continued from Prior Part)Irwin D. Simon Irwin D. Simon emerged as the key figure for Aphria (APHA) amid all the negative press the company got late in December. Aphria appointed Simon as the independent
Why Aphria Could Squeeze Out Short Sellers(Continued from Prior Part) Back to fundamentals With the approval of new facilities, Aphria (APHA) now has a total annualized capacity of 110,000 kilograms annually, which is huge compared to peers Canopy
Why Aphria Could Squeeze Out Short Sellers(Continued from Prior Part)Short sellers’ claims Aphria (APHA) received severe criticism from short sellers late last year over its acquisition in Latin America. Short sellers even rushed to call Aphria
Many investors see a big opportunity in marijuana. Alas, it is not as simple as buying a handful of marijuana stocks on good news. Sen. Cory Booker, a Democratic presidential candidate, is reintroducing a bill that would legalize marijuana at the federal level.
Why Aphria Could Squeeze Out Short SellersAphria moves higherOn March 4, Aphria (APHA) was among the few cannabis stocks that ended in the green with an increase of almost 2.7% to 13.85 Canadian dollars. The stock was moving higher upon Aphria
Has MedMen Stock Bottomed Out?(Continued from Prior Part)Analysts’ recommendations After MedMen Enterprises (MMEN) (MMNFF) posted its second-quarter earnings for fiscal 2019 on February 27, Canaccord Genuity lowered its 12-month price target to
CORAL GABLES, FL / ACCESSWIRE / March 5, 2019 / It's hard to believe how successful the marijuana stock market has become in such a short time. Given the infancy of the cannabis industry, typically markets don't have the level of excitement surrounding them like we continue to see with marijuana stocks. Premier Health Group (OTC:PHGRF) (CSE:PHGI), India Globalization Capital Inc (IGC), Aurora Cannabis Inc (ACB), and Aphria Inc (APHA) represent 4 cannabis companies worth looking into on Tuesday.